Cost‐effectiveness of first‐line versus second‐line use of domestic anti‐PD‐1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non‐small cell lung cancer

Abstract Background Programmed cell death protein‐1/programmed cell death ligand‐1 (PD‐1/L1) inhibitor is a promising therapeutic option that can be used as either a first‐line or second‐line treatment for driver‐negative advanced or metastatic squamous non‐small cell lung cancers (sqNSCLC). However...

Full description

Bibliographic Details

Published in:	Cancer Medicine
Main Authors:	Rihua Cheng, Zhen Zhou, Qiao Liu
Format:	Article
Language:	English
Published:	Wiley 2023-03-01
Subjects:	China cost‐effectiveness domestic anticancer drugs NSCLC sintilimab
Online Access:	https://doi.org/10.1002/cam4.5440